Search Results 1341-1350 of 18701 for Relapse
... relapsed multiple myeloma in routine medical practice with a treatment strategies that include a proteasome inhibitor (PI) and/or immunomodulatory drug ...
The addition of CAR-T, as well as other cellular based therapy, has significantly improved the outcomes of patient with relapsed or refractory diseases. A ...
... relapsed/refractory multiple myeloma (RRMM). A Dose Escalation Study of Amivantamab in Participants with Advanced Non-Small Cell Lung Cancer Rochester, MN.
This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 (AMP-514) in participants with relapsed or refractory ...
... relapsed/refractory Non-Hodgkin's lymphomas or advanced solid tumors. ... It is ... DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Relapse ...
The main objective of this study is to evaluate the effectiveness of venetoclax in combination with azacitidine to improve Relapse Free Survival (RFS) in ...
Mantle cell lymphoma; Follicular lymphoma; Multiple myeloma. People who have relapsed or refractory disease may be eligible for CAR-T cell therapy. Possible ...
This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT ( ...
The purpose of this study is to evaluate the magnitude of financial toxicity in newly diagnosed and relapsed multiple myeloma (MM) and amyloidosis (AL) patients ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.